EX-99.1 2 ex99-1.htm EX-99.1

 
 

Afya Limited Announces Third-Quarter and Nine Months 2022 Financial Results

Guidance On Track

Robust EPS Expansion


Nova Lima, Brazil, November 21, 2022 – Afya Limited (Nasdaq: AFYA) (“Afya” or the “Company”), the leading medical education group and digital health services provider in Brazil, reported today financial and operating results for the three and nine-month period ended September 30, 2022 (third quarter 2022). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS).

 

 

Third Quarter 2022 Highlights

§3Q22 Adjusted Net Revenue increased 25.2% YoY to R$580.2 million. Adjusted Net Revenue excluding acquisitions grew 17.1%, reaching R$542.4 million.
§3Q22 Adjusted EBITDA increased 19.5% YoY, reaching R$228.7 million, with an Adjusted EBITDA Margin of 39.4%. Adjusted EBITDA excluding acquisitions grew 10.2%, reaching R$211.0 million, with an Adjusted EBITDA Margin of 38.9%.
§3Q22 Adjusted Net Income increased 2.7% YoY, reaching R$120.1 million, with an EPS growth of 47.4% in the same period.

Nine Months 2022 Highlights

§9M22 Adjusted Net Revenue increased 38.2% YoY to R$1,724.0 million. Adjusted Net Revenue excluding acquisitions grew 15.6%, reaching R$1,441.5 million.
§9M22 Adjusted EBITDA increased 28.6% YoY reaching R$719.7 million, with an Adjusted EBITDA Margin of 41.7%. Adjusted EBITDA excluding acquisitions grew 5.3%, reaching R$589.2 million, with an Adjusted EBITDA Margin of 40.9%.
§9M22 Adjusted Net Income increased 18.8% YoY, reaching R$406.4 million, with an EPS growth of 77.5% in the same period.
§Cash conversion of 104.6%, with a solid cash position of R$715.6 million.
§~286 thousand monthly active physicians and medical students using Afya’s Digital Services, an increase of 15.7% over the same period of last year.
Table 1: Financial Highlights                      
  For the three months period ended September 30,   For the nine months period ended September 30,
(in thousand of R$) 2022 2022 Ex Acquisitions* 2021 % Chg  % Chg Ex Acquisitions   2022 2022 Ex Acquisitions* 2021 % Chg  % Chg Ex Acquisitions
(a) Net Revenue 580,575 542,810 454,387 27.8% 19.5%   1,745,055 1,462,585 1,221,112 42.9% 19.8%
(b) Adjusted Net Revenue (1) 580,198 542,433 463,278 25.2% 17.1%   1,723,993 1,441,523 1,247,321 38.2% 15.6%
(c) Adjusted EBITDA (2) 228,730 210,968 191,400 19.5% 10.2%   719,717 589,167 559,709 28.6% 5.3%
(e) = (c)/(b)  Adjusted EBITDA Margin 39.4% 38.9% 41.3% -190 bps -240 bps   41.7% 40.9% 44.9% -320 bps -400 bps
                       
*For the three months period ended September 30, 2022, "2022 Ex Acquisitions" excludes: UNIGRANRIO (only July, 2022; Closing of UNIGRANRIO was in August, 2021), RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic (all from July to September, 2022; Closing of RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic were after October, 2021).
*For the nine months period ended September 30, 2022, "2022 Ex Acquisitions" excludes: iClinic (only January, 2022; Closing of iClinic was in January, 2021), Medicinae (from January to March, 2022; Closing of Medicinae was in March, 2021), Cliquefarma (from January to April, 2022; Closing of Cliquefarma was in April, 2021), Medical Harbour (from January to April, 2022; Closing of Medical Harbour was in April, 2021), Shosp (from January to May, 2022; Closing of Shosp was in May, 2021), UNIFIPMoc and FIP Guanambi (from January to May, 2022; Closing of UNIFIPMoc and FIP Guanambi was in June, 2021), UNIGRANRIO (from January to July, 2022; Closing of UNIGRANRIO was in August, 2021), RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic (all from January to September, 2022; Closing of RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic were after October, 2021).
(1) Includes mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction, and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision.
(2) See more information on "Non-GAAP Financial Measures" (Item 08).
   
  1
 
 
1.Message from Management

As we approach the end of the year, we can gladly see Afya delivering strong results again. This quarter was marked by significant increases in net revenue in our three segments, positive EBITDA, cash generation and EPS growth, and a consistent business expansion. All these factors combined enable us to reassure our 2022 guidance, reinforcing our business strategy execution.

Back in the third quarter of 2021, we were hoping to see the pandemic lose its strength. Now, in 2022, we can finally see our students, employees, and partners extracting the best from our ecosystem again. After the opening of six new Continuing Education campuses – a segment that was impacted during COVID-19 times -, we can see, for the third time this year, an incredible recovery compared to last year, with strong intake processes, new campuses and courses maturation, and our practical classes boosting again.

On the Undergrad side of the education segment, we can also see important movements. First, the successful opening of four Mais Médicos campuses – Abaetetuba, Bragança, Itacoatiara, and Manacapuru -, along with UniSL Ji-Parana campus, all of them combined totaling 228 new medical seats to our portfolio this quarter, allowing us to reach an impressive number of 2,709 medical operating seats, strengthening our consolidation as the medical undergrad leader in Brazil. Second, to further boost this leadership, on October 13rd, we announced the entering into a share purchase agreement for our largest acquisition so far, UNIT Alagoas and FITS Jaboatão dos Guararapes, adding 340 more medical seats to our base. With the conclusion of this acquisition, will increase our 2,759 approved seats to 3,099. And third, the completeness of Unigranrio’s integration process also in October, one year after its acquisition, proving our commitment to extracting synergies within the operation. All this effort means one thing: our medical education business remains, and will continue to be, the cornerstone of our business in the short and middle terms, delivering highly predicted growth combined with strong profitability and cash generation.

On our Digital Services segment, we are proud to see another quarter of strong inorganic and organic growth. Afya’s Digital Health Services is being able to help physicians’ during their medical journey and now, with our 6 pillars complete after the acquisition of Glic, we will further explore the development of our ecosystem, which is being built with multiple offerings, unlocking new interactions and revenue streams that go beyond the physicians, achieving pharma players, hospitals, labs and drugstores chains, scratching the surface of a total addressable market of R$28.4 billion. Since the beginning of the year, we have been disclosing our B2P and B2B figures, breaking down our Digital Service’s net revenue within these two for a better perspective.

As a reflection of our great results and actions that are being shown to the market, we are also glad to announce that, for the third time in a row, we’ve won the “Anuário Época Negócios 360º” award as the best Company in the Education segment. We are very proud of this achievement, as it is the recognition of the work and passion of our more than nine thousand employees around a unique vision: to transform health together with those who have medicine as a vocation.

With another round of high and sustainable growth, our mission remains solid as ever: to provide an ecosystem that integrates education and digital solutions for the entire medical journey, enhancing the development, updating, assertiveness, and productivity of health professionals. We are very proud of our business and of what we have achieved so far, as well as excited about what we are planning for the future. 

 

 

2.Subsequent Events in the Quarter:
§Afya announced on October 13th, 2022, that it has entered into a share purchase agreement for the acquisition of 100% of the total share capital of Sociedade Educacional e Cultural Sergipe DelRey Ltda., that encompasses the operations of Centro Universitário Tiradentes Alagoas ("UNIT Alagoas”) and Faculdade Tiradentes Jaboatão dos Guararapes ("FITS Jaboatão dos Guararapes”). The acquisition will contribute 340 medical school seats to Afya, increasing Afya’s total medical school seats from 2,759 to 3,099. The aggregate purchase price (enterprise value) is R$825.0 million before the deduction of Net Debt that will be calculated at the closing date, and it will be paid as follows: R$575 million in cash on the transaction closing date and R$250 million in three annual installments, respectively, of R$150 million, R$50 million, and R$50 million, adjusted by the Brazilian interest rate (SELIC). We expected an EV/EBITDA of 5.8x at maturity and post synergies (2024). With the acquisition, Afya further consolidates its presence in the Brazilian Northeast, entering a new state in the region.

 

 

   
  2
 
 
3.Full Year 2022 Guidance Reaffirmed

 

The Company is reaffirming its previously issued guidance for FY22 including the successfully concluded acceptances of new medical students for the second semester, ensuring 100% occupancy in all of its medical schools.

 

 

The guidance for FY2022 is defined in the following table:

 
Guidance for 2022 Important considerations
2022  Adjusted Net Revenue is expected to be between R$2,280.0 million – R$2,360.0 million Includes four Mais Médicos units start operating in 2H22;
Includes Ji-Parana acquisition start operating in the 2H22;
Includes Além da Medicina acquisition;
Excludes any acquisition that may be concluded after the issuance of the guidance, such as Cardiopapers and Glic.
2022 Adjusted EBITDA is expected to be between R$935.0 million - R$1,015 million

 

 

4.9M22 Overview

 

Operational Review

Afya is the only company offering educational and technological solutions to support physicians across every stage of their medical career, from undergraduate students in their medical school years through medical residency preparatory courses, medical specialization programs, and continuing medical education. The Company also offers solutions to empower physicians in their daily routine including supporting clinic decisions through mobile app subscription, delivering practice management tools through a Software as a Service (SaaS) model, and assisting physicians in their relationship with their patients.

The Company reports results for three distinct business units. The first, Undergrad – medical schools, other healthcare programs, and ex-health degrees. Revenue is generated from the monthly tuition fees the Company charges students enrolled in the undergraduate programs. The second, Continuing Education – specialization programs and graduate courses for physicians. Revenue is also generated from the monthly tuition fees the Company charges students enrolled in the specialization and graduate courses. The third is Digital Services – digital services offered by the Company at every stage of the medical career. This business unit is divided into Business to Physician (which encompasses Content & Technology for Medical Education, Clinical Decision Software, Practice Management Tools & Electronic Medical Records, Physician-Patient Relationship, Telemedicine, and Digital Prescription) and Business to Business (which provides access and demand for the healthcare players). Revenue is generated from printed books and e-books, and is recognized at the point in time when control is transferred to the customer, and subscription fees, which are recognized as the services are transferred over time.

 

   
  3
 
 

Key Revenue Drivers – Undergraduate Courses

 

Table 2: Key Revenue Drivers Nine months period ended September 30,
  2022 2021 % Chg
Undergrad Programs      
MEDICAL SCHOOL      
Approved Seats                            2,759                         2,611 5.7%
Operating Seats                             2,709                         2,361 14.7%
Total Students (end of period)                         17,997                      15,977 12.6%
Average Total Students                         17,692                      13,983 26.5%
Average Total Students (ex-Acquisitions)*                         15,237                      13,983 9.0%
Tuition Fees (Total - R$MM)                  1,522,393              1,081,135 40.8%
Tuition Fees (ex- Acquisitions* - R$MM)                  1,282,263              1,081,135 18.6%
Medical School Gross Avg. Ticket (ex- Acquisitions* - R$/month)                            9,351                         8,591 8.8%
Medical School Net Avg. Ticket (ex- Acquisitions* - R$/month)                            7,765                         7,109 9.2%
UNDERGRADUATE HEALTH SCIENCE      
Total Students (end of period)                         18,114                      19,297 -6.1%
Average Total Students                         19,932                      14,587 36.6%
Average Total Students (ex-Acquisitions)*                         14,401                      14,587 -1.3%
Tuition Fees (Total - R$MM)                      254,613                   163,270 55.9%
Tuition Fees (ex- Acquisitions* - R$MM)                      167,925                   163,270 2.9%
OTHER UNDERGRADUATE       
Total Students (end of period)                         23,085                      26,953 -14.4%
Average Total Students                         23,746                      18,533 28.1%
Average Total Students (ex-Acquisitions)*                         14,190                      18,533 -23.4%
Tuition Fees (Total - R$MM)                      201,116                   161,063 24.9%
Tuition Fees (ex- Acquisitions* - R$MM)                      135,500                   161,063 -15.9%
TOTAL TUITION FEES      
Tuition Fees (Total - R$MM)                  1,978,122              1,405,468 40.7%
Tuition Fees (ex- Acquisitions* - R$MM)                  1,585,688              1,405,468 12.8%
       
*For the nine months period ended September 30, 2022, "2022 Ex Acquisitions" excludes: UNIFIPMoc and FIP Guanambi (from January to May, 2022; Closing of UNIFIPMoc and FIP Guanambi was in June, 2021), UNIGRANRIO (from January to July, 2022; Closing of UNIGRANRIO was in August, 2021), and Garanhuns (from January to September, 2022; Closing of Garanhuns was in November, 2021).

 

   
  4
 
 

Key Revenue Drivers – Continuing Education and Digital Services

Table 3: Key Revenue Drivers Nine months period ended September 30,
  2022 2021 % Chg
Continuing Education      
Medical Specialization & Others      
Total Students (end of period) 4,036 2,835 42.4%
Average Total Students 3,686 3,273 12.6%
Average Total Students (ex-Acquisitions) 3,686 3,273 12.6%
Net Revenue from courses (Total - R$MM) 75,568 51,481 46.8%
Net Revenue from courses (ex- Acquisitions¹) 75,568 51,481 46.8%
Digital Services      
Content & Technology for Medical Education      
Medcel Active Payers      
Prep Courses & CME - B2P 12,886 16,878 -23.7%
Prep Courses & CME - B2B 5,704 4,097 39.2%
Além da Medicina Active Payers 5,696  - n.a.
Cardio Papers Active Payers 5,090  - n.a.
Medical Harbour Active Payers 5,080  306 1560.1%
Clinical Decision Software      
Whitebook Active Payers 133,926 117,826 13.7%
Clinical Management Tools²      
iClinic Active Payers 22,596 15,984 41.4%
Shosp Active Payers 2,348 2,093 12.2%
       
Digital Services Total Active Payers (end of period) 193,326 157,184 23.0%
Net Revenue from Services (Total - R$MM) 134,243 109,613 22.5%
Net Revenue - B2P 117,256 103,596 13.2%
Net Revenue - B2B 16,987 6,017 182.3%
Net Revenue From Services (ex-Acquisitions¹) 111,050 109,613 1.3%
(1) For the nine months period ended September 30, 2022, "2022 Ex Acquisitions" excludes: iClinic (only January, 2022; Closing of iClinic was in January, 2021), Medicinae (from January to March, 2022; Closing of Medicinae was in March, 2021), Cliquefarma (from January to April, 2022; Closing of Cliquefarma was in April, 2021), Medical Harbour (from January to April, 2022; Closing of Medical Harbour was in April, 2021), Shosp (from January to May, 2022; Closing of Shosp was in May, 2021), RX PRO, Além da Medicina, Cardiopapers, and Glic (all from January to September, 2022; Closing of RX PRO, Além da Medicina, Cardiopapers, and Glic were after October, 2021).
(2) Clinical management tools includes Telemedicine and Digital Prescription features. 

 

   
  5
 
 

Key Operational Drivers – Digital Services

 

Monthly Active Users (MaU) represents the number of unique individuals that consumed Digital Services content in each one of our products in the last 30 days of a specific period.

Total monthly active users reached 286 thousand, 15.7% higher over the same period in the last year.

Monthly Unique Active Users (MuaU) represents the number of unique individuals, without overlap of users among products, in the last 30 days of a specific period. Since this concept is being implemented this year, the historical metrics of MuaU could not be disclosed.

Table 4: Key Operational Drivers for Digital Services - Monthly Active Users (MaU)
  3Q22 3Q21 % Chg YoY 2Q22 % Chg QoQ
Content & Technology for Medical Education   21,811   20,015 9.0%  20,739 5.2%
Clinical Decision Software   239,640   194,082 23.5%  221,862 8.0%
Clinical Management Tools¹   23,036   32,909 -30.0%  21,151 8.9%
Physician-Patient Relationship   1,397  -  n.a.  1,101 26.9%
Total Monthly Active Users (MaU) - Digital Services   285,884   247,006 15.7%  264,853 7.9%
1) Clinical management tools includes Telemedicine and Digital Prescription features
2) Clinical management tools MAU excludes other users other than payors, starting in 1Q22
3) Shosp, Medicinae and Além da Medicina starting in 1Q22
4) Cardiopapers and Glic starting in 2Q22

 

Table 5: Key Operational Drivers for Digital Services - Monthly Unique Active Users (MuaU)  
    3Q22
Total Monthly Unique Active Users (MuaU) - Digital Services                    263,587
1) Total Monthly Unique Active Users excludes non-integrated companies: Medical Harbour, Medicinae, Shosp, Além da Medicina, Cardiopapers and Glic

Seasonality

Undergrad’s and Continuing Education tuition revenues are related to the intake process and monthly tuition fees charged to students over the period thus the Company does not have significant fluctuations during the semester. Digital Services is comprised mostly by Medcel, Pebmed and iClinic revenues. While Pebmed and iClinic do not have significant fluctuation regarding seasonality, Medcel’s revenue is concentrated in the first and last quarter of the year, as a result of the enrollments of Medcel’s clients period. The majority of Medcel’s revenues are derived from printed books and e-books, which are recognized at the point in time when control is transferred to the customer. Consequently, the Digital Services segment generally has higher revenues and results of operations in the first and last quarters of the year compared to the second and third quarters of the year.

 

Revenue

As disclosed in our 2Q22 earnings release, the Company has been recovering amounts related to mandatory discounts in tuition fees previously granted by individual and collective legal proceedings and public civil proceedings related to COVID-19. For the nine months period ended September 30, 2022, this amount represents R$21.1 million, and, as Afya has excluded these mandatory discounts from Adjusted Net Revenue in 2020 and 2021, this recovery is not counted for Adjusted Net Revenue in 2022.

 

Adjusted Net Revenue for the third quarter of 2022 was R$580.2 million, an increase of 25.2% over the same period of the prior year. Excluding acquisitions, Adjusted Net Revenue in the third quarter increased 17.1% YoY to R$542.4 million, a strong increase, mainly due to the maturation of medical seats and the beginning of the 4 Mais Médicos operations during the third quarter, higher tickets in Medicine courses, and the Continuing Education recovery, which ended the third quarter with a 72.2% year over year increase in net revenue, mainly due to the strong student base expansion during 2022.

 

 

   
  6
 
 

Once again, the Digital Services segment has also contributed to the Adjusted Net Revenues growth this quarter, increasing 59.4% year over year, and 30.4%, excluding acquisitions. This organic growth is a combination of (a) a great start of the B2B engagements, reaching 61 contracts – including pharma solutions and RX PRO contracts -, with 40 different pharmaceutical industry companies, and (b) the expansion of the active payers in the B2P, mainly in Whitebook and iClinic.

 

For the nine-month period ended September 30, 2022, Adjusted Net Revenue was R$1,724.0 million, an increase of 38.2% over the same period of last year. Excluding acquisitions, Adjusted Net Revenue in the nine-month period increased 15.6% YoY to R$1,441.5 million.

 

Table 6: Revenue & Revenue Mix                         
(in thousands of R$)   For the three months period ended September 30,   For the nine months period ended September 30,
    2022 2022 Ex Acquisitions* 2021 % Chg % Chg Ex Acquisitions   2022 2022 Ex Acquisitions* 2021 % Chg % Chg Ex Acquisitions
Net Revenue Mix                        
Undergrad   509,097 479,424 410,059 24.2% 16.9%   1,538,037 1,278,760 1,060,345 45.1% 20.6%
Adjusted Undergrad¹   508,720 479,047 418,950 21.4% 14.3%   1,516,975 1,257,698 1,086,554 39.6% 15.8%
Continuing Education   27,906 27,906 16,209 72.2% 72.2%   75,568 75,568 51,481 46.8% 46.8%
Digital Services   44,548 36,456 27,948 59.4% 30.4%   134,243 111,050 109,613 22.5% 1.3%
 Inter-segment transactions   -976 -976   171 n.a. -670.8%   -2,793 -2,793 -327 754.1% 754.1%
Total Reported Net Revenue   580,575 542,810 454,387 27.8% 19.5%   1,745,055 1,462,585 1,221,112 42.9% 19.8%
Total Adjusted Net Revenue ¹   580,198 542,433 463,278 25.2% 17.1%   1,723,993 1,441,523 1,247,321 38.2% 15.6%
*For the three months period ended September 30, 2022, "2022 Ex Acquisitions" excludes: UNIGRANRIO (only July, 2022; Closing of UNIGRANRIO was in August, 2021), RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic (all from July to September, 2022; Closing of RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic were after October, 2021).
*For the nine months period ended September 30, 2022, "2022 Ex Acquisitions" excludes: iClinic (only January, 2022; Closing of iClinic was in January, 2021), Medicinae (from January to March, 2022; Closing of Medicinae was in March, 2021), Cliquefarma (from January to April, 2022; Closing of Cliquefarma was in April, 2021), Medical Harbour (from January to April, 2022; Closing of Medical Harbour was in April, 2021), Shosp (from January to May, 2022; Closing of Shosp was in May, 2021), UNIFIPMoc and FIP Guanambi (from January to May, 2022; Closing of UNIFIPMoc and FIP Guanambi was in June, 2021), UNIGRANRIO (from January to July, 2022; Closing of UNIGRANRIO was in August, 2021), RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic (all from January to September, 2022; Closing of RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic were after October, 2021).
(1) Includes mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction, and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision.
(2) See more information on "Non-GAAP Financial Measures" (Item 08).

 


Adjusted EBITDA

 

Adjusted EBITDA for the three-month period ended September 30, 2022 increased 19.5% to R$228.7 million, up from R$191.4 million in the same period of the prior year, while the Adjusted EBITDA Margin decreased 190 basis points to 39.4%. For the nine-month period ended September 30, 2022, Adjusted EBITDA was R$719.7 million, an increase of 28.6% over the same period of the prior year, with an Adjusted EBITDA Margin decrease of 320 basis points in the same period. The Adjusted EBITDA Margin reduction is due to (a) the Digital segment, mostly in the performance of Medcel in the residency preparatory market, (b) the expansion of the Continuing Education segment, which is still maturing the new campuses, and (c) the increase in corporate expenses in the period.

 

Excluding acquisitions, Adjusted EBITDA for the three-month period increased 10.2% YoY to R$211.0 million, while the Adjusted EBITDA Margin decreased 240 basis points to 38.9%. For the nine-month period, excluding acquisitions, Adjusted EBITDA increased 5.3% YoY to R$589.2 million, while the Adjusted EBITDA Margin decreased 400 basis points to 40.9%, mainly due to the same reasons previously explained.

 

Table 7: Adjusted EBITDA                      
(in thousands of R$) For the three months period ended September 30,   For the nine months period ended September 30,
  2022 2022 Ex Acquisitions* 2021 % Chg % Chg Ex Acquisitions   2022 2022 Ex Acquisitions* 2021 % Chg % Chg Ex Acquisitions
Adjusted EBITDA 228,730 210,968 191,400 19.5% 10.2%   719,717 589,167 559,709 28.6% 5.3%
% Margin 39.4% 38.9% 41.3% -190 bps -240 bps   41.7% 40.9% 44.9% -320 bps -400 bps
*For the three months period ended September 30, 2022, "2022 Ex Acquisitions" excludes: UNIGRANRIO (only July, 2022; Closing of UNIGRANRIO was in August, 2021), RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic (all from July to September, 2022; Closing of RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic were after October, 2021).
*For the nine months period ended September 30, 2022, "2022 Ex Acquisitions" excludes: iClinic (only January, 2022; Closing of iClinic was in January, 2021), Medicinae (from January to March, 2022; Closing of Medicinae was in March, 2021), Cliquefarma (from January to April, 2022; Closing of Cliquefarma was in April, 2021), Medical Harbour (from January to April, 2022; Closing of Medical Harbour was in April, 2021), Shosp (from January to May, 2022; Closing of Shosp was in May, 2021), UNIFIPMoc and FIP Guanambi (from January to May, 2022; Closing of UNIFIPMoc and FIP Guanambi was in June, 2021), UNIGRANRIO (from January to July, 2022; Closing of UNIGRANRIO was in August, 2021), RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic (all from January to September, 2022; Closing of RX PRO, Garanhuns, Além da Medicina, Cardiopapers, and Glic were after October, 2021).

 

   
  7
 
 

Adjusted Net Income

Net Income for the third quarter of 2022 was R$80.4 million, an increase of 38.7% over the same period of the prior year. For the nine-month period ended September 30, 2022, Net Income increased 66.3%, from R$193.3 million to R$321.4 million, mainly due to: (a) the increase in operational results, as previously described, (b) the recovery of a portion of the prior granted discounts in tuition fees related to COVID-19, (c) the reduction of financial expenses related to the fx rate difference regarding the Softbank transaction that affected 2Q21, and (d) the reduction on the non-recurring M&A expenses.

 

Adjusted Net Income for the third quarter of 2022 was R$120.1 million, an increase of 2.7% over the same period of the prior year. Adjusted Net Income for the nine-month period of 2022 was R$406.4 million, an increase of 18.8% year over year.

 

Our EPS reached R$3.39 per share for the nine-month period ended September 30, 2022, an increase of 77.5% year over year, reflecting the increase in our Net Income, and capital allocation discipline executing our business combination and three buyback programs in a row.

 

Table 8: Adjusted Net Income              
(in thousands of R$) For the three months period ended September 30,   For the nine months period ended September 30,
  2022 2021 % Chg   2022 2021 % Chg
Net income 80,410 57,989 38.7%     321,425 193,282 66.3%
Amortization of customer relationships and trademark (1) 18,952 18,031 5.1%     55,959 46,015 21.6%
Share-based compensation  8,833 8,847 -0.2%     20,414 33,949 -39.9%
Non-recurring expenses: 11,861 32,008 -62.9%     8,586 68,726 -87.5%
 - Integration of new companies (2) 7,063 5,192 36.0%     17,015 12,728 33.7%
 - M&A advisory and due diligence (3) 1,388 8,442 -83.6%     3,194 11,998 -73.4%
 - Expansion projects (4) 1,079 3,069 -64.8%     2,358 6,459 -63.5%
 - Restructuring expenses (5) 2,708 6,414 -57.8%     7,081 11,332 -37.5%
 - Mandatory Discounts in Tuition Fees  (6) -377 8,891 n.a.   - 21,062 8,891 n.a.
Adjusted Net Income 120,056 116,875 2.7%   406,384 341,972 18.8%
               
Basic earnings per share - in R$ (7) 0.84 0.57 47.4%   3.39 1.91 77.5%
Adjusted earnings per share - in R$ (8) 1.28 1.20 6.7%   4.33 3.50 23.7%
(1) Consists of amortization of customer relationships and trademark recorded under business combinations.
(2) Consists of expenses related to the integration of newly acquired companies.
(3) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions.
(4) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.
(5) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of our acquired companies.
(6) Consists of  mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction, and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision.
(7) Basic earnings per share: Net Income/Weighted average number of outstanding shares.
(8) Adjusted earnings per share: Adjusted Net Income attributable to equity holders of the Parent/Weighted average number of outstanding shares.

 

Cash and Debt Position

 

Cash and cash equivalents on September 30, 2022, was R$715.6 million, a decrease of 31.1% over the same period in 2021.

 

For the nine-month period ended September 30, 2022, Afya reported Adjusted Cash Flow from Operations of R$743.8 million, up from R$557.2 million in the same period of the previous year, an increase of 33.5% YoY, boosted by the solid operational results.

 

Operating Cash Conversion Ratio was strong once again, achieving 104.6% for the nine-month period ended September 30, 2022, compared to 113.5% in the same period of the previous year. This decrease was mainly related to (a) an increase in the trade receivables, partially caused by the recovery of the mandatory discounts in tuition fees related to COVID-19 that were invoiced but not yet received, and (b) the fact that last year’s cash performance was positively impacted by the recover of the special payment conditions related to the COVID-19 given to our students during 2020.

   
  8
 
 

On September 30, 2022, net debt, excluding the effect of IFRS 16, totaled R$1,348.2 million, compared with net debt of R$1,108.6 million in the same period in 2021, mainly due to payments related to (a) 6 business combinations and license acquisitions executed in the last 12 months, totaling R$263.7 million; (b) shares repurchase program of R$267.5 million, executed in the last 12 months, (c) investments activities in properties, equipment and intangibles (excluding license acquisitions and goodwill) totaling R$228.1 million in the last 12 months, and (d) net financial results from the last 12 months, which totaled R$235.8 million, all partially offset by the R$818.1 million cash generation from September 30, 2021 through September 30, 2022. The following table shows more information regarding the cost of debt for the third quarter, considering loans and financing, and accounts payable to selling shareholders. It is important to mention that our capital structure remains solid with a conservative leveraging position and a low cost of debt.

 

Table 9: Gross Debt and Cost of Debt  
(in R$ MM) For the nine months period ended September 30,
      Cost of Debt
  Gross Debt Duration (Years) per year %CDI*
Loans and financing: Softbank 824 3.6 6.5% 55%
Loans and financing: Others 575 0.8 13.7% 114%
Accounts payable to selling shareholders
plus other financial obligations		 664 1.3 11.6% 97%
Total 2.063 2.2 10.0% 84.0%
*Based on the annualized Interbank Certificates of Deposit ("CDI") rate for the period as a reference.
9M22: ~11.97% p.y.

 

Table 10: Operating Cash Conversion Ratio Reconciliation For the nine months period ended September 30,
(in thousands of R$) Considering the adoption of IFRS 16 
  2022 2021 % Chg
(a) Cash flow from operations 715,881 528,698 35.4%
(b) Income taxes paid 27,940 28,495 -1.9%
(c) = (a) + (b) Adjusted cash flow from operations 743,821 557,193 33.5%
       
(d) Adjusted EBITDA 719,717 559,709 28.6%
(e) Non-recurring expenses: 8,586 68,726 -87.5%
 - Integration of new companies (1) 17,015 12,728 33.7%
 - M&A advisory and due diligence  (2) 3,194 11,998 -73.4%
 - Expansion projects (3) 2,358 6,459 -63.5%
 - Restructuring Expenses (4) 7,081 11,332 -37.5%
 - Mandatory Discounts in Tuition Fees  (5) -21,062 26,209 n.a.
(f) = (d) - (e) Adjusted EBITDA ex- non-recurring expenses  711,131 490,983 44.8%
(g) = (c) / (f) Operating cash conversion ratio 104.6% 113.5% -890 bps
(1) Consists of expenses related to the integration of newly acquired companies. 
(2) Consists of expenses related to professional and consultant fees in connection with due diligence services for M&A transactions.
(3) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.
(4) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of acquired companies.
(5) Consists of  mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction, and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision.

 

   
  9
 
 

 

Table 11: Cash and Debt Position          
(in thousands of R$)          
  3Q22 FY2021 % Chg 3Q21 % Chg
(+) Cash and Cash Equivalents 715,644 748,562 -4.4% 1,038,934 -31.1%
Cash and Bank Deposits   27,161   88,487 -69.3%   75,635 -64.1%
Cash Equivalents   688,483   660,075 4.3%   963,299 -28.5%
(-) Loans and Financing 1,399,724 1,374,876 1.8% 1,377,810 1.6%
Current   259,638   128,720 101.7%   14,780 1656.7%
Non-Current 1,140,086 1,246,156 -8.5% 1,363,030 -16.4%
(-) Accounts Payable to Selling Shareholders   598,367   679,826 -12.0%   696,521 -14.1%
Current   241,560   239,849 0.7%   247,819 -2.5%
Non-Current   356,807   439,977 -18.9%   448,702 -20.5%
(-) Other Short and Long Term Obligations 65,748 72,726 -9.6% 73,212 -10.2%
(=) Net Debt (Cash) excluding IFRS 16 1,348,195 1,378,866 -2.2% 1,108,609 21.6%
(-) Lease Liabilities 782,224 714,085 9.5% 675,895 15.7%
Current   28,685   24,955 14.9%   24,169 18.7%
Non-Current   753,539   689,130 9.3%   651,726 15.6%
Net Debt (Cash) with IFRS 16 2,130,419 2,092,951 1.8% 1,784,504 19.4%

 

CAPEX

Capital expenditures is consisting of the purchase of property and equipment and intangible assets, including expenditures mainly related to the expansion and maintenance of our campuses and headquarters including leasehold improvements, and the development of new solutions in the digital segment, among others.

 

For the nine-month period ending September 30, 2022, CAPEX went from R$140.7 million to R$238.4 million, an increase of 69.4% over the same period of the prior year, due to higher expenditures related to intangible assets, mainly explained by the R$24.4 million earn-out related to the 28 additional seats of Centro Universitário São Lucas, in Ji-Parana, approved in March, 2022, and R$39.1 million remeasurement of Unigranrio's business combination goodwill.

 

Table 12: CAPEX
(in thousands of R$) For the nine months period ended September 30,
  2022 2021 % Chg
CAPEX 238,369 140,725 69.4%
Property and equipment 116,641 97,435 19.7%
Intanglibe assets 121,728 43,290 181.2%
 - Licenses 24,408 - n.a.
 - Goodwill 39,100 - n.a.
 - Others 58,220 43,290 34.5%

 

ESG Metrics

ESG commitment is an important part of Afya’s strategy and permeates the Company’s core values. Afya has been advancing year after year on its core pillars and, since 2021, ESG metrics have been disclosed in the Company’s quarterly financial results.

   
  10
 
 

In August 2021, Afya assumed a voluntary commitment to have at least 50% women in its management positions by 2030. In addition, Afya announced that it was certificated by Women on Board, an independent initiative whose purpose is to acknowledge, value and promote corporate environments in which women are part of the board of directors. The company voluntarily committed to continuing to have at least two women as board members.

On January 2022, Afya announced that it is one of 418 companies across 45 countries and regions to join the 2022 Bloomberg Gender-Equality Index (GEI), a modified market capitalization-weighted index that aims to track the performance of public companies committed to transparency in gender-data reporting. This reference index measures gender equality across five pillars: female leadership & talent pipeline, equal pay & gender pay parity, inclusive culture, anti-sexual harassment policies, and pro-women brand. Afya was included on this year’s index for scoring above a global threshold established by Bloomberg to reflect disclosure and the achievement or adoption of best-in-class statistics and policies.

The 2021 Sustainability Report can be found at: https://ir.afya.com.br/ >> Corporate Governance >> Sustainability.

Table 12: ESG Metrics¹³⁴ 3Q22 3Q21 2021 2020 2019
# GRI Governance and Employee Management          
1 405-1 Number of employees 9,039 8,177  8,079  6,100  3,369
2 405-1 Percentage of female employees 57% 55% 55% 55% 57%
3 405-1 Percentage of female members in the board of directors 27% 18% 18% 18% 22%
4 102-24 Percentage of independent member in the board of directors 36% 36% 36% 36% 22%
    Environmental          
4 302-1 Total energy consumption (kWh)   4,355,340 3,172,655   12,176,966   8,035,845   5,928,450
4.1 302-1 Consumption per campus 98,985 99,145   385,573   321,434   395,230
5 302-1 % supplied by distribution companies 71.6% 89.8% 91.3% 83.4% 96.2%
6 302-1 % supplied by other sources² 28.4% 10.2% 8.7% 16.6% 3.8%
    Social          
8 413-1 Number of free clinical consultations offered by Afya   128,686   144,832   341,286   427,184   270,000
9   Number of physicians graduated in Afya's campuses  17,176  12,359  16,772  12,691  8,306
10 201-4 Number of students with financing and scholarship programs (FIES and PROUNI)  10,329  7,940  7,881  4,999  2,808
11   % students with scholarships over total undergraduate students 17.4% 13.0% 12.9% 13.7% 11.7%
12 413-1 Hospital, clinics and city halls partnerships  481  432  447  432 60
               
(1) Some factors can influence in the adequate proportionality analysis of data over the years, such as: climate changes, COVID-19 pandemic effects, seasonalities, number of employees, number of students, number of active units, among others.
(2) "Other sources" refers to: (a) Derived from renewable sources, such as solar panels installed in the units; and (b) Derived from the search for alternative energy options in the market.
(3) Starting in 2Q22, previously disclosed environmental data were updated to consider: (a) GHG Protocol guidelines improvements, and (b) additional data-collection criteria refinements.
(4) Starting in 2Q22, previously disclosed social data were updated to consider: (a) the number of graduated physicians considering all units after its closing, and (b) partnerships related only to medical schools.

 

5.                  Conference Call and Webcast Information

When: November 21, 2022 at 5:00 p.m. ET.

Who:  

Mr. Virgilio Gibbon, Chief Executive Officer

Mr. Luis André Blanco, Chief Financial Officer

 

Webcast: https://afya.zoom.us/j/92548247907

 

OR

 

Dial-in:   Brazil: +55 11 4700 9668 or +55 21 3958 7888 or +55 11 4632 2236 or +55 11 4632 2237 or +55 11 4680 6788

 

United States: +1 646 931 3860 or +1 929 205 6099 or +1 301 715 8592 or +1 309 205 3325 or +1 312 626 6799 or +1 669 444 9171 or +1 669 900 6833 or +1 719 359 4580 or +1 253 215 8782 or +1 346 248 7799 or +1 386 347 5053 or +1 564 217 2000

 

Webinar ID: 925 4824 7907

 

Other Numbers: https://afya.zoom.us/u/abwfMV1H7z 

 

   
  11
 
 

 

6.                  About Afya Limited (Nasdaq: AFYA)

Afya is a leading medical education group in Brazil based on the number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering digital products to help doctors enhance their healthcare services through their whole career. For more information, please visit www.afya.com.br.

 

7.                  Forward – Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements other than statements of historical fact could be deemed forward looking, and include risks and uncertainties related to statements about our competition; our ability to attract, upsell and retain students; our ability to increase tuition prices and prep course fees; our ability to anticipate and meet the evolving needs of students and professors; our ability to source and successfully integrate acquisitions; general market, political, economic, and business conditions; and our financial targets such as revenue, share count and IFRS and non-IFRS financial measures including gross margin, operating margin, net income (loss) per diluted share, and free cash flow. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the potential impacts of the COVID-19 pandemic on our business operations, financial results and financial position and the Brazilian economy.

 

The Company undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. The achievement or success of the matters covered by such forward-looking statements involves known and unknown risks, uncertainties and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from the results expressed or implied by the forward-looking statements we make. Readers should not rely upon forward-looking statements as predictions of future events. Forward-looking statements represent management’s beliefs and assumptions only as of the date such statements are made. Further information on these and other factors that could affect the Company’s financial results are included in the filings made with the United States Securities and Exchange Commission (SEC) from time to time, including the section titled “Risk Factors” in the most recent Rule 434(b) prospectus. These documents are available on the SEC Filings section of the investor relations section of our website at: https://ir.afya.com.br/.

 

8.                  Non-GAAP Financial Measures

To supplement the Company's consolidated financial statements, which are prepared and presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board—IASB, Afya uses Adjusted EBITDA and Operating Cash Conversion Ratio information, which are non-GAAP financial measures, for the convenience of investors. A non-GAAP financial measure is generally defined as one that intends to measure financial performance but excludes or includes amounts that would not be equally adjusted in the most comparable GAAP measure.

 

Afya calculates Adjusted EBITDA as net income plus/minus net financial result plus income taxes expense plus depreciation and amortization plus interest received on late payments of monthly tuition fees, plus share-based compensation plus/minus share of income of associate plus/minus non-recurring expenses. The calculation of Adjusted Net Income is net income plus amortization of customer relationships and trademark, plus share-based compensation. We calculate Operating Cash Conversion Ratio as the cash flow from operations, adjusted with income taxes paid divided by Adjusted EBITDA plus/minus non-recurring expenses.

 

Management presents Adjusted EBITDA, because it believes these measures provide investors with a supplemental measure of financial performance of the core operations that facilitates period-to-period comparisons on a consistent basis. Afya also presents Operating Cash Conversion Ratio because it believes this measure provides investors with a measure of how efficiently the Company converts EBITDA into cash. The non-GAAP financial measures described in this prospectus are not a substitute for the IFRS measures of earnings. Additionally, calculations of Adjusted EBITDA and Operating Cash Conversion Ratio may be different from the calculations used by other companies, including competitors in the education services industry, and therefore, Afya’s measures may not be comparable to those of other companies.

   
  12
 
 

9.                  Investor Relations Contact

E-mail: ir@afya.com.br

 

 

 

   
  13
 
 

 

10.              Financial Tables

Unaudited interim condensed consolidated statements of financial position
As of September 30, 2022, and December 31, 2021
(In thousands of Brazilian reais)

  September 30, 2022   December 31, 2021
Assets (unaudited)    
Current assets      
Cash and cash equivalents 715,644   748,562
Trade receivables 405,450   378,351
Inventories 12,488   11,827
Recoverable taxes 42,510   25,579
Other assets 37,874   42,533
Total current assets 1,213,966   1,206,852
       
Non-current assets      
Trade receivables 34,218   27,442
Other assets 198,700   180,306
Investment in associate 55,900   48,477
Property and equipment 503,626   419,808
Right-of-use assets 712,068   663,686
Intangible assets 4,042,545   3,900,835
Total non-current assets 5,547,057   5,240,554
       
Total assets 6,761,023   6,447,406
       
Liabilities      
Current liabilities      
Trade payables 62,905   59,098
Loans and financing 259,638   128,720
Lease liabilities 28,685   24,955
Accounts payable to selling shareholders 241,560   239,849
Notes payable 17,333   14,478
Advances from customers 108,588   114,585
Labor and social obligations 202,040   131,294
Taxes payable 24,170   26,715
Income taxes payable 27,353   11,649
Other liabilities 4,532   15,163
Total current liabilities 976,804   766,506
       
Non-current liabilities      
Loans and financing 1,140,086   1,246,156
Lease liabilities  753,539   689,130
Accounts payable to selling shareholders 356,807   439,977
Notes payable 48,415   58,248
Taxes payable 93,445   96,598
Provision for legal proceedings 205,151   148,287
Other liabilities 12,962   2,486
Total non-current liabilities 2,610,405   2,680,882
Total liabilities 3,587,209   3,447,388
       
Equity      
Share capital 17   17
Additional paid-in capital 2,375,344   2,375,344
Share-based compensation reserve 114,515   94,101
Treasury stock (304,947)   (152,630)
Retained earnings 938,192   631,317
Equity attributable to equity holders of the parent 3,123,121   2,948,149
Non-controlling interests 50,693   51,869
Total equity 3,173,814   3,000,018
       
Total liabilities and equity 6,761,023   6,447,406
   
  14
 
 

 

Unaudited interim condensed consolidated statements of income and comprehensive income
For the three and nine-month periods ended September 30, 2022 and 2021
(In thousands of Brazilian reais, except earnings per share)

 

  Three-month period ended Nine-month period ended
  September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021
  (unaudited)  (unaudited)  (unaudited)  (unaudited) 
Net revenue 580,575 454,387 1,745,055 1,221,112
Cost of services (216,691) (180,042) (622,663) (450,993)
Gross profit 363,884 274,345 1,122,392 770,119
         
General and administrative expenses (210,692) (178,811) (596,621) (444,399)
Other (expenses) income, net (7,173) (135) (8,739) 1,163
         
Operating income 146,019 95,399 517,032 326,883
         
  Finance income 29,202 29,161 76,618 45,144
  Finance expenses (91,933) (64,558) (256,873) (168,825)
Finance result (62,731) (35,397) (180,255) (123,681)
         
Share of income of associate 3,819 3,004 10,260 8,626
         
Income before income taxes 87,107 63,006 347,037 211,828
         
Income taxes expenses (6,697) (5,017) (25,612) (18,546)
         
Net income 80,410 57,989 321,425 193,282
         
Other comprehensive income - - - -
Total comprehensive income 80,410 57,989 321,425 193,282
         
Income attributable to        
  Equity holders of the parent 75,760 53,030 306,875 178,357
  Non-controlling interests 4,650 4,959 14,550 14,925
  80,410 57,989 321,425 193,282
Basic earnings per share        
Per common share 0.84 0.57 3.39 1.91

Diluted earnings per share

Per common share

 0.84 0.56 3.38 1.89

 

   
  15
 
 

Unaudited interim condensed consolidated statements of cash flows
For the nine-month periods ended September 30, 2022 and 2021
(In thousands of Brazilian reais)

  September 30, 2022 September 30, 2021
Operating activities (unaudited) (unaudited) 
  Income before income taxes 347,037 211,828
    Adjustments to reconcile income before income taxes    
      Depreciation and amortization 151,706 112,204
      Write-off of property and equipment 683 1,936
      Write-off of intangible assets 6 1,049
      Allowance for doubtful accounts 29,441 34,005
      Share-based compensation expense 20,414 33,949
      Net foreign exchange differences 293 18,376
      Accrued interest 147,839 66,851
      Accrued lease interest 63,458 47,738
      Share of income of associate (10,260) (8,626)
      Provision for legal proceedings 8,531 9,286
Changes in assets and liabilities    
  Trade receivables (60,167) (18,593)
  Inventories (661) (1,232)
  Recoverable taxes (16,931) (8,228)
  Other assets 5,858 (11,264)
  Trade payables 1,398 3,461
  Taxes payables 10,709 (1,247)
  Advances from customers (16,075) 9,419
  Labor and social obligations 70,608 54,005
  Other liabilities (10,066) 2,276
    743,821 557,193
  Income taxes paid (27,940) (28,495)
       
  Net cash flows from operating activities 715,881 528,698
       
Investing activities    
  Acquisition of property and equipment (116,641) (97,435)
  Acquisition of intangibles assets (70,423) (43,290)
  Dividends received 2,837 5,770
  Acquisition of subsidiaries, net of cash acquired (242,752) (925,279)
  Restricted cash - 8,103
  Net cash flows used in investing activities (426,979) (1,052,131)
     
Financing activities    
  Payments of loans and financing (68,975) (130,446)
  Issuance of loans and financing - 809,539
  Payments of lease liabilities (84,509) (61,909)
  Treasury shares (152,317) (98,541)
  Proceeds from exercise of stock options - 32,721
  Dividends paid to non-controlling interests (15,726) (15,663)
  Net cash flows from (used in) financing activities (321,527) 535,701
  Net foreign exchange differences (293) (18,376)
  Net increase in cash and cash equivalents (32,918) (6,108)
  Cash and cash equivalents at the beginning of the period 748,562 1,045,042
  Cash and cash equivalents at the end of the period 715,644 1,038,934
   
  16
 
 

Reconciliation between Net Income and Adjusted EBITDA

 

Reconciliation between Adjusted EBITDA and Net Income              
               
(in thousands of R$) For the three months period ended September 30,   For the nine months period ended September 30,
  2022 2021 % Chg   2022 2021 % Chg
Net income 80,410 57,989 38.7%   321,425 193,282 66.3%
Net financial result 62,731 35,397 77.2%   180,255 123,681 45.7%
Income taxes expense 6,697 5,017 33.5%   25,612 18,546 38.1%
Depreciation and amortization 52,617 45,289 16.2%   151,706 112,204 35.2%
Interest received (1) 9,400 9,857 -4.6%   21,979 17,947 22.5%
Income share associate (3,819) (3,004) 27.1%   (10,260) (8,626) 18.9%
Share-based compensation 8,833 8,847 -0.2%   20,414 33,949 -39.9%
Non-recurring expenses: 11,861 32,008 -62.9%   8,586 68,726 -87.5%
 - Integration of new companies (2) 7,063 5,192 36.0%   17,015 12,728 33.7%
 - M&A advisory and due diligence (3) 1,388 8,442 -83.6%   3,194 11,998 -73.4%
 - Expansion projects (4) 1,079 3,069 -64.8%   2,358 6,459 -63.5%
 - Restructuring expenses (5) 2,708 6,414 -57.8%   7,081 11,332 -37.5%
 - Mandatory Discounts in Tuition Fees  (6) (377) 8,891 n.a.   (21,062) 26,209 n.a.
Adjusted EBITDA 228,730 191,400 19.5%   719,717 559,709 28.6%
Adjusted EBITDA Margin 39.4% 41.3% -190 bps   41.7% 44.9% -320 bps
(1) Represents the interest received on late payments of monthly tuition fees.
(2) Consists of expenses related to the integration of newly acquired companies.
(3) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions.
(4) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses.
(5) Consists of expenses related to the employee redundancies in connection with the organizational restructuring of our acquired companies.
(6) Consists of  mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID 19 on site classes restriction, and excludes any recovery of these discounts that were invoiced based on the Supreme Court decision.

 

 

   
  17